ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BPCR Biopharma Credit Plc

0.842
0.00 (0.00%)
04 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.842 0.838 0.844 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 135.74M 108.45M 0.0833 7.88 854.56M

BioPharma Credit PLC STATEMENT RE COHERUS BIOSCIENCES, INC.

10/05/2024 3:11pm

RNS Regulatory News


RNS Number : 0397O
BioPharma Credit PLC
10 May 2024
 

BioPharma Credit PLC

10 May 2024

 

 

 

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

STATEMENT RE Coherus BIOSCIENCES, Inc.

 

Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released 9 May 2024 by Coherus Biosciences, Inc. ("Coherus") regarding entering into a combined term loan and product royalty financing agreement with Barings (the "New Financing"). The New Financing allowed Coherus to fully pay off its remaining USD$75 million senior secured term loan, of which the Company had an investment of USD$37.5 million.  

 

The Company had previously announced on 10 January 2022 an investment in a senior secured loan to Coherus of up to USD$150 million in up to three tranches. The Company had previously funded US$125 million, of which USD$87.5 million was repaid as referenced in the Company's announcement on 6 February 2024. The remaining USD$37.5 million was repaid to the Company in connection with the New Financing. In connection with this final repayment, the Company received US$39.8 million in total, including USD$2.3 million of accrued interest, and prepayment and make-whole fees.

 

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUBUAUPCGCU

1 Year Biopharma Credit Chart

1 Year Biopharma Credit Chart

1 Month Biopharma Credit Chart

1 Month Biopharma Credit Chart